


## Stereotactic Ablative Radiotherapy (SABR) for Treatment of Primary Cancer and Metastases



Robert D. Timmerman, M.D.  
Department of Radiation Oncology

**UT SOUTHWESTERN** Univ. of Texas Southwestern Medical Center  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Disclosures

- I have research grants/funding with:
  - Accuray, Inc.
  - Elekta Oncology
  - Varian Medical Systems
  - US NIH
  - US DOD
  - Cancer Prevention Research Institute of Texas
- I am on the scientific advisory board for:
  - D3 Corporation

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---


---

---

---

Which of the following statements regarding dose response relationships for ablative radiotherapy delivery is FALSE

1. Dose response relationships are best determined by phase I clinical trials
2. Small dose increase may result in large toxicity increase in the transition range of the dose response curve.
3. The Maximum Tolerated Dose (MTD) corresponds to the most ideal therapeutic ratio.
4. A negative therapeutic window results when efficacy is less likely than harm.




---

---

---

---

---


---

---

---

Early stage lung cancer was the most common clinical model studied in clinical trials testing SABR at centers across the world. The Indiana University trials demonstrated that treatments in the central chest were problematic for patients to tolerate likely related to:

1. Impairment of the pulmonary toilet function of the central chest.
2. Higher dose used for central tumors
3. Larger tumors generally occurring in the central chest
4. Differential tolerance of parallel vs. secular defined thoracic structures




---

---

---

---

---

---

---

---

Based on published reports, what factors would be most concerning for increased risk of toxicity after SABR?

- 24% 1. impaired spirometry
- 14% 2. peripheral lung location
- 45% 3. impaired DLCO
- 16% 4. advanced age

---

---

---

---

---


---

---

---

The following are true statements about the outcome of patients with early stage lung cancer treated with SBRT?

1. Local control for this treatment is predicted to be >80%.
2. Risk of grade 3 or higher toxicity is around 20% at 3 years.
3. Overall survival in most series is 60-75% at 2 years.
4. All of the above




---

---

---

---

---


---

---

---

The rationale and conduct for SABR treatment in metastatic cancer to the liver includes all of the following except:

1. Treatment intent is to improve survival, even cure.
2. Previous chemotherapy clearly limits tolerance and is a contraindication to using SABR in patients with liver metastases.
3. The University of Colorado multicenter trials used the critical volume methodology to avoid liver toxicity
4. Dose tolerance of the liver is similar to treatments in the lung




## New Cancer Therapy Assessments


- Eventually measure survival and quality of life
- Along the way:
  - Formulate (how should it be prescribed)
  - Optimize (maximize the therapeutic window)
- In therapies with variable potency, need to characterize dose response

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## Dose Response



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Stereotactic Ablative Radiotherapy

- aka, extracranial stereotactic radioablation (ESR), stereotactic body radiation therapy (SBRT), etc
- SABR
  - Fitting
  - Descriptive
- Includes a "potpourri" of technologies to allow optimal immobilization, motion control, targeting, dose deposition, and accuracy to deliver oligofractionated radiotherapy

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## Original Experience with SABR

- Innovations from US (Hamilton), Sweden (Lax and Blomgren) and Japan (Uematsu) in 1990s
- Treatment effect impressive
  - >10 Gy per fraction
  - Amazing tumor regression
- Needed systematic approach to find proper place

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## Evaluating Technology

- In the case SABR, many technologies (all evolving)
- Characterized the treatment effect (physically and biologically) and created guidelines
- Formed hypotheses:
  - SABR technologies MIGHT enable delivery of ablative oligofractionated radiotherapy
  - Ablative radiotherapy will control tumors better than conventional radiotherapy or chemoradiotherapy
  - Toxicity will be increased, particularly in the late timeframe, but generally tolerable and offset by benefits

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

## Clonogenic Survival



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---


---

---

---

---

## High Risk Hypothesis



LATE radiation toxicity: ulceration, denervation, devascularization, stenosis, fibrosis, devitalization

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Best Data Collection Approach

- Valid, prospective, clinical scientific investigation
  - Hypothesis testing within a defined "clinical model"
  - Adult supervision (e.g., statistician, research manager, etc)
  - Independent scrutiny (IRB, data safety monitoring committee, other specialty input, etc)
  - Complete record-keeping (research staff, audits, etc.)
  - Phase I, II, III randomized, and III randomized
- Next best is population cohort and prospective registry
- Much further below is retrospective registries and chart reviews (non-conclusive, only hypothesis generating)

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Clinical Model: Early Stage Lung CA

- Risk groups based on surgery
- 3 broad groups:
  - Average Risk  
Generally can tolerate removal of an entire lobe
  - High Risk  
Can tolerate partial removal of a lobe
  - Medically Inoperable  
Cannot tolerate surgery for lung cancer

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## Medically Inoperable Lung Cancer

- **Generally, frail patients**



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## 3-5 Year Outcome in Early Stage Lung Cancer

	<u>Rx Modality</u>	<u>% alive</u>
• Stage I	Surgery	60-80%
Stage I*	Conventional XRT	15-45%

	<u>Rx Modality</u>	<u>% LC</u>
• Stage I	Surgery	60-90%
Stage I	Conventional XRT	15-45%

\*clinically staged and mostly medically inoperable  
(significantly confounded by those who refused surgery)

Conventional RT generally 60-66 Gy delivered in 6-7 weeks

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---



## SABR in Early Stage NSCLC

- First prospective trials were in medically inoperable patients with stage I NSCLC
- Intent, originally, was to improve tumor control
  - probably at the expense of increased toxicity
- Experience has been that tumor control is improved and treatment is surprisingly well tolerated

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---


## Extracranial Stereotactic Radioablation\*

Results of a Phase I Study in Medically Inoperable Stage I Non-small Cell Lung Cancer

Robert Timmerman, MD; Lech Papiez, PhD; Ronald McGarry, MD;  
Laura Lake, RT; Colleen DeRoosiers, MS; Stephanie Frost, MS; and  
Mark Williams, MD

(CHEST 2003; 124:1946-1955)

- Classic phase I design
- Low starting dose 8 Gy X 3 = 24 Gy
- 3 separate tumor size categories
- Dose escalation to very high doses 20-24 Gy X 3 = 60-72 Gy



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---


---

---

---

---

## Indiana Univ. Phase I Trial



Pre-Treatment  
12 Gy X 3 = 36 Gy

22 mo. Post-Treatment

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

VOLUME 24 • NUMBER 20 • OCTOBER 20 2006

**JOURNAL OF CLINICAL ONCOLOGY** ORIGINAL REPORT

**Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer**

*Robert Timmerman, Ronald McGarry, Christopher Flamowitz, Leah Piquet, Kathy Tashir, Jill DeLoe, Marlene Dwyer, Robert Abshire, Colleen Daddario, Mark Williams, and James Hickey*

- IU 70 patient phase II study
- 20 Gy X 3 for T1
- 22 Gy X 3 for T2
- NO restriction on tumor location

Fig 1. Kaplan-Meier plot of time from treatment until local failure (percent with local control).

Fig 2. Kaplan-Meier plot of overall survival (OS).

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Zone of the Proximal Bronchial Tree





Fig 4. Kaplan-Meier plot of time from treatment until grade 3 to 5 treatment-related toxicity comparing patients with tumors in the central (perihilar and central mediastinal) regions from those with more peripheral tumors.

• Increased pneumonia, hypoxia, decline in PFT, and even death

• Likely related to impairment of pulmonary toilet at the junction between sterile and non-sterile bronchi



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY


## RTOG 0236

- Non-small cell lung cancer - biopsy proven  
*Only invasive step*
- T1, T2 ( $\leq 5$  cm) and T3 (chest wall only,  $\leq 5$  cm), N0, M0 Staging was non-invasive (PET/CT)
- Medical problems preclude surgery (e.g. emphysema, heart disease, diabetes)
- No other planned therapy

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## Primary Tumor Control

One patient failed within 2 cm of the primary tumor



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## Local Control

- Local recurrence is primary tumor failure and/or failure within the involved lobe of the lung
- 1 patient had primary tumor failure  
+  
3 patients had failure within the involved lobe
- 3-year Kaplan Meier local control = 90.7%

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Regional Recurrence

- 2 patients have reported a regional failure, both after 2 years (2.8 and 3.0 years)
- Patients avoiding both local and regional recurrence (loco-regional control) is 87.2%

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---


---

---

---

---

## Overall Survival



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Severe Toxicity

- No grade 5 toxicities (treatment deaths)
- Two (4%) grade 4 protocol specified toxicity (decline in PFTs to <25% predicted & hypocalcemia)
- Seven (13%) grade 3 protocol specified toxicities

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## Protocol Specified Grade 3 Toxicities

- 1 patient: low oxygen in blood (O<sub>2</sub> required)
- 2 patient: radiation inflammation of lung (O<sub>2</sub> required)
- 3 patients: decline in pulmonary function, (25-50% of predicted value)
- 1 patient: decline in pulmonary function and cough

**= 7 patients (all pulmonary toxicity)**

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## **JAMA**® Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer

Robert Timmerman; Rebecca Paulus; James Galvin; et al.

JAMA. 2010;303(11):1070-1076 (doi:10.1001/jama.2010.261)

- SABR has become a standard of care for medically inoperable patients
  - Up to 10,000 patients per year in US
- Successful clinical model using hypofractionated radiotherapy:
  - Rigorously conducted, highly scrutinized
  - Multicenter QA
  - Rapid acceptance

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

## Multicenter Phase II Trials Medically Inoperable

- Dutch Investigators
  - 206 patients with Stage I
  - Risk adapted approach well tolerated
  - Primary tumor recurrence 3%, regional failure 9%, 2 year OS 64%
- JCOG 0403
  - Peripheral T1a, N0, M0
  - 100 patients – still enrolling
- Nordic Study Group
  - peripheral T1-T2, N0, M0
  - completed accrual of 57 patients 9/2005
  - Primary tumor recurrence 7%, 2 year OS 65%

**SW** SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

VOLUME 28 • NUMBER 35 • DECEMBER 10, 2010

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

### Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis

David Palma, Otto Visser, Frank J. Lagerwaard, Jose Belderbos, Ben J. Slotman, and Suresh Senan


- Next best thing to a phase III randomized trial
  - Included all patients > 75 years old diagnosed with stage I lung cancer in Amsterdam
- 875 patients analyzed in 3 eras
  - 1999-2001 (pre SABR), 2002-2004 (some SABR), 2005-2007 (full SABR access)
- 299 patients got surgery, 299 RT (conventional or SABR), 277 neither

**SW** SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

## Dutch Population Study

- From 1999 to 2007, utilization of RT increased significantly, 26% to 42%
  - No change in surgery, corresponding change in those untreated
- Those getting SABR as a form of RT increased from 23% to 55%
- Median overall survival for all patients increased from 16 to 21 months
  - All of the improvement came from the RT treated group

**SW** SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY




---

---

---

---

---

---

---

---

### RTOG Strategies

- Refine SABR for medically inoperable patients
  - RTOG 0813 (Central Tumors – Bezjak, PI)
  - RTOG 0915 (Peripheral Tumors – Videtic/Chang, PIs)  
Completed accrual
- Explore use of SABR in “high risk” operable patient subset
  - RTOG 0618 (Peripheral Tumors – Timmerman, PI)  
Completed accrual
  - ACOSOG Z4099 / RTOG 1021  
Opened May 2, 2011

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

### “High Risk” Operable AKA “Marginally” Operable

Who are they?

- Poor cardiopulmonary (CP) reserve
- Will have difficulty during and after a lobectomy or pneumonectomy
  - Getting off ventilator
  - Getting out of hospital
  - Readmissions
  - Decreased vitality/quality of life post-resection (“Grandpa was never the same ...”)

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Challenges

- Historical bias
  - Stage I NSCLC has been a “surgical disease”
- Disparate therapies
  - Incisions vs. non-invasive
  - Inpatient vs. outpatient
- Technically rigorous
  - Need established and effective QA for both Rx's

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Expanding SABR beyond the lung

- Lung cancer was the original clinical model
  - Established a new standard of care in medically inoperable population
- Could this approach be duplicated for other cancers in need of higher cure rates?
  - Metastases to the liver and lung
  - Pancreas
  - Etc.
- What about palliation?
  - Spine

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---



## Curative Treatment of Metastases: A new (huge) indication for radiotherapy?

- Not talking about palliation at end of life
- Conventional fractionated radiotherapy has little role
  - Field size and volumes much too large (too toxic)
  - Attempts to use CFRT in liver mets (Hopkins, Univ of Michigan were unimpressive)
- Focused, ablative treatments using oligofractionation have promise
  - Basis in surgical resection
  - Some patients are clearly "cured"

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Liver Metastases

- Similar story to SABR lung



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## A PHASE I TRIAL OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR LIVER METASTASES

TRACEY E. SCHEPETER, M.D.,<sup>1</sup> BRIAN D. KAVANAGH, M.D., M.P.H.,<sup>2</sup> ROBERT D. TIDMERMANN, M.D.,<sup>1</sup>  
HEGEMIA R. CARDENES, M.D.,<sup>1</sup> ANNA BARON, Ph.D.,<sup>3</sup> AND LAURIE E. GASPAR, M.D., M.B.A.<sup>4</sup>  
Int. J. Radiation Oncology Biol. Phys., Vol. 62, No. 5, pp. 1371-1378, 2005

- Multicenter prospective dose finding study
- Opened late 2001
- 3 fractions starting at 36 Gy
  - Waiting periods for toxicity
  - Introduced 'critical volume' liver constraint
- Variety of tumor histologies (mostly CRC)
- 18 patients enrolled to 5 levels up to 60 Gy (20 Gy per fraction)
  - No dose limiting toxicity (MTD not reached)

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

VOLUME 27 • NUMBER 10 • APRIL 1 2009


JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases

Kyle E. Rusthoven, Brian D. Kavanagh, Higinia Cardenas, Volker W. Stieber, Stuart H. Burri, Steven J. Feigenberg, Mark A. Chidal, Thomas J. Pugh, Wilbur Franklin, Madeleine Kane, Laurie E. Gaspar, and Tracey E. Scheffer

- 63 lesions in 47 patients
- 3 fraction regimen
- Poor risk group at entry:
  - 40% multiple
  - Most on 2<sup>nd</sup> and 3<sup>rd</sup> line systemic therapy
  - 45% had extrahepatic disease at study entry
- Median follow-up 16 months (6-54 months)

SOUTHWESTERN

DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

Multi-Institutional Phase II Trial

A

Local Control

100

80

60

40

20

0

0 6 12 18 24 30 36 42 48

Time (months)

B

Local Control

100

80

60

40

20

0

0 6 12 18 24 30 36 42 48

Time (months)

A

Overall Survival (%)

100

80

60

40

20

0

0 6 12 18 24 30 36 42 48

Time (months)

B

Overall Survival (%)

100

80

60

40

20

0

0 6 12 18 24 30 36 42 48

Time (months)

Lesions at risk

40 40 30 17 7 5 3 2 1

0.2 cm

0.2-1 cm

1.1-2 cm

2.1-3 cm

3.1-4 cm

4.1-5 cm

5.1-6 cm

6.1-7 cm

7.1-8 cm

8.1-9 cm

9.1-10 cm

10.1-11 cm

11.1-12 cm

12.1-13 cm

13.1-14 cm

14.1-15 cm

15.1-16 cm

16.1-17 cm

17.1-18 cm

18.1-19 cm

19.1-20 cm

20.1-21 cm

21.1-22 cm

22.1-23 cm

23.1-24 cm

24.1-25 cm

25.1-26 cm

26.1-27 cm

27.1-28 cm

28.1-29 cm

29.1-30 cm

30.1-31 cm

31.1-32 cm

32.1-33 cm

33.1-34 cm

34.1-35 cm

35.1-36 cm

36.1-37 cm

37.1-38 cm

38.1-39 cm

39.1-40 cm

40.1-41 cm

41.1-42 cm

42.1-43 cm

43.1-44 cm

44.1-45 cm

45.1-46 cm

46.1-47 cm

47.1-48 cm

48.1-49 cm

49.1-50 cm

50.1-51 cm

51.1-52 cm

52.1-53 cm

53.1-54 cm

54.1-55 cm

55.1-56 cm

56.1-57 cm

57.1-58 cm

58.1-59 cm

59.1-60 cm

60.1-61 cm

61.1-62 cm

62.1-63 cm

63.1-64 cm

64.1-65 cm

65.1-66 cm

66.1-67 cm

67.1-68 cm

68.1-69 cm

69.1-70 cm

70.1-71 cm

71.1-72 cm

72.1-73 cm

73.1-74 cm

74.1-75 cm

75.1-76 cm

76.1-77 cm

77.1-78 cm

78.1-79 cm

79.1-80 cm

80.1-81 cm

81.1-82 cm

82.1-83 cm

83.1-84 cm

84.1-85 cm

85.1-86 cm

86.1-87 cm

87.1-88 cm

88.1-89 cm

89.1-90 cm

90.1-91 cm

91.1-92 cm

92.1-93 cm

93.1-94 cm

94.1-95 cm

95.1-96 cm

96.1-97 cm

97.1-98 cm

98.1-99 cm

99.1-100 cm

100.1-101 cm

101.1-102 cm

102.1-103 cm

103.1-104 cm

104.1-105 cm

105.1-106 cm

106.1-107 cm

107.1-108 cm

108.1-109 cm

109.1-110 cm

110.1-111 cm

111.1-112 cm

112.1-113 cm

113.1-114 cm

114.1-115 cm

115.1-116 cm

116.1-117 cm

117.1-118 cm

118.1-119 cm

119.1-120 cm

120.1-121 cm

121.1-122 cm

122.1-123 cm

123.1-124 cm

124.1-125 cm

125.1-126 cm

126.1-127 cm

127.1-128 cm

128.1-129 cm

129.1-130 cm

130.1-131 cm

131.1-132 cm

132.1-133 cm

133.1-134 cm

134.1-135 cm

135.1-136 cm

136.1-137 cm

137.1-138 cm

138.1-139 cm

139.1-140 cm

140.1-141 cm

141.1-142 cm

142.1-143 cm

143.1-144 cm

144.1-145 cm

145.1-146 cm

146.1-147 cm

147.1-148 cm

148.1-149 cm

149.1-150 cm

150.1-151 cm

151.1-152 cm

152.1-153 cm

153.1-154 cm

154.1-155 cm

155.1-156 cm

156.1-157 cm

157.1-158 cm

158.1-159 cm

159.1-160 cm

160.1-161 cm

161.1-162 cm

162.1-163 cm

163.1-164 cm

164.1-165 cm

165.1-166 cm

166.1-167 cm

167.1-168 cm

168.1-169 cm

169.1-170 cm

170.1-171 cm

171.1-172 cm

172.1-173 cm

173.1-174 cm

174.1-175 cm

175.1-176 cm

176.1-177 cm

177.1-178 cm

178.1-179 cm

179.1-180 cm

180.1-181 cm

181.1-182 cm

182.1-183 cm

183.1-184 cm

184.1-185 cm

185.1-186 cm

186.1-187 cm

187.1-188 cm

188.1-189 cm

189.1-190 cm

190.1-191 cm

191.1-192 cm

192.1-193 cm

193.1-194 cm

194.1-195 cm

195.1-196 cm

196.1-197 cm

197.1-198 cm

198.1-199 cm

199.1-200 cm

200.1-201 cm

201.1-202 cm

202.1-203 cm

203.1-204 cm

204.1-205 cm

205.1-206 cm

206.1-207 cm

207.1-208 cm

208.1-209 cm

209.1-210 cm

210.1-211 cm

211.1-212 cm

212.1-213 cm

213.1-214 cm

214.1-215 cm

215.1-216 cm

216.1-217 cm

217.1-218 cm

218.1-219 cm

219.1-220 cm

220.1-221 cm

221.1-222 cm

222.1-223 cm

223.1-224 cm

224.1-225 cm

225.1-226 cm

226.1-227 cm

227.1-228 cm

228.1-229 cm

229.1-230 cm

230.1-231 cm

231.1-232 cm

232.1-233 cm

233.1-234 cm

234.1-235 cm

235.1-236 cm

236.1-237 cm

237.1-238 cm

238.1-239 cm

239.1-240 cm

240.1-241 cm

241.1-242 cm

242.1-243 cm

243.1-244 cm

244.1-245 cm

245.1-246 cm

246.1-247 cm

247.1-248 cm

248.1-249 cm

249.1-250 cm

250.1-251 cm

251.1-252 cm

252.1-253 cm

253.1-254 cm

254.1-255 cm

255.1-256 cm

256.1-257 cm

257.1-258 cm

258.1-259 cm

259.1-260 cm

260.1-261 cm

261.1-262 cm

262.1-263 cm

263.1-264 cm

264.1-265 cm

265.1-266 cm

266.1-267 cm

267.1-268 cm

268.1-269 cm

269.1-270 cm

270.1-271 cm

271.1-272 cm

272.1-273 cm

273.1-274 cm

274.1-275 cm

275.1-276 cm

276.1-277 cm

277.1-278 cm

278.1-279 cm

279.1-280 cm

280.1-281 cm

281.1-282 cm

282.1-283 cm

283.1-284 cm

284.1-285 cm

285.1-286 cm

286.1-287 cm

287.1-288 cm

288.1-289 cm

289.1-290 cm

290.1-291 cm

291.1-292 cm

292.1-293 cm

293.1-294 cm

294.1-295 cm

295.1-296 cm

296.1-297 cm

297.1-298 cm

298.1-299 cm

299.1-300 cm

300.1-301 cm

301.1-302 cm

302.1-303 cm

303.1-304 cm

304.1-305 cm

305.1-306 cm

306.1-307 cm

307.1-308 cm

308.1-309 cm

309.1-310 cm

310.1-311 cm

311.1-312 cm

312.1-313 cm

313.1-314 cm

314.1-315 cm

315.1-316 cm

316.1-317 cm

317.1-318 cm

318.1-319 cm

319.1-320 cm

320.1-321 cm

321.1-322 cm

322.1-323 cm

323.1-324 cm

324.1-325 cm

325.1-326 cm

326.1-327 cm

327.1-328 cm

328.1-329 cm

329.1-330 cm

330.1-331 cm

331.1-332 cm

332.1-333 cm

333.1-334 cm

334.1-335 cm

335.1-336 cm

336.1-337 cm

337.1-338 cm

338.1-339 cm

339.1-340 cm

340.1-341 cm

341.1-342 cm

342.1-343 cm

343.1-344 cm

344.1-345 cm

345.1-346 cm

346.1-347 cm

347.1-348 cm

348.1-349 cm

349.1-350 cm

350.1-351 cm

351.1-352 cm

352.1-353 cm

353.1-354 cm

354.1-355 cm

355.1-356 cm

356.1-357 cm

357.1-358 cm

358.1-359 cm

359.1-360 cm

360.1-361 cm

361.1-362 cm

362.1-363 cm

363.1-364 cm

364.1-365 cm

365.1-366 cm

366.1-367 cm

367.1-368 cm

368.1-369 cm

369.1-370 cm

370.1-371 cm

371.1-372 cm

372.1-373 cm

373.1-374 cm

374.1-375 cm

375.1-376 cm

376.1-377 cm

377.1-378 cm

378.1-379 cm

379.1-380 cm

380.1-381 cm

381.1-382 cm

382.1-383 cm

383.1-384 cm

384.1-385 cm

385.1-386 cm

386.1-387 cm

387.1-388 cm

388.1-389 cm

389.1-390 cm

390.1-391 cm

391.1-392 cm

392.1-393 cm

393.1-394 cm

394.1-395 cm

395.1-396 cm

396.1-397 cm

397.1-398 cm

398.1-399 cm

399.1-400 cm

400.1-401 cm

401.1-402 cm

402.1-403 cm

403.1-404 cm

404.1-405 cm

405.1-406 cm

406.1-407 cm

407.1-408 cm

408.1-409 cm

409.1-410 cm

410.1-411 cm

411.1-412 cm

412.1-413 cm

413.1-414 cm

414.1-415 cm

415.1-416 cm

416.1-417 cm

417.1-418 cm

418.1-419 cm

419.1-420 cm

420.1-421 cm

421.1-422 cm

422.1-423 cm

423.1-424 cm

424.1-425 cm

425.1-426 cm

426.1-427 cm

427.1-428 cm

428.1-429 cm

429.1-430 cm

430.1-431 cm

431.1-432 cm

432.1-433 cm

433.1-434 cm

434.1-435 cm

435.1-436 cm

436.1-437 cm

437.1-438 cm

438.1-439 cm

439.1-440 cm

440.1-441 cm

441.1-442 cm

442.1-443 cm

443.1-444 cm

444.1-445 cm

445.1-446 cm

446.1-447 cm

447.1-448 cm

448.1-449 cm

449.1-450 cm

450.1-451 cm

451.1-452 cm

452.1-453 cm

453.1-454 cm

454.1-455 cm

455.1-456 cm

456.1-457 cm

457.1-458 cm

458.1-459 cm

459.1-460 cm

460.1-461 cm

461.1-462 cm

462.1-463 cm

463.1-464 cm

464.1-465 cm

465.1-466 cm

466.1-467 cm

467.1-468 cm

468.1-469 cm

469.1-470 cm

470.1-471 cm

471.1-472 cm

472.1-473 cm

473.1-474 cm

474.1-475 cm

475.1-476 cm

476.1-477 cm

477.1-478 cm

478.1-479 cm

479.1-480 cm

480.1-481 cm

481.1-482 cm

482.1-483 cm

483.1-484 cm

484.1-485 cm

485.1-486 cm

486.1-487 cm

487.1-488 cm

488.1-489 cm

489.1-490 cm

490.1-491 cm

491.1-492 cm

492.1-493 cm

493.1-494 cm

494.1-495 cm

495.1-496 cm

496.1-497 cm

497.1-498 cm

498.1-499 cm

499.1-500 cm

500.1-501 cm

501.1-502 cm

502.1-503 cm

503.1-504 cm

504.1-505 cm

505.1-506 cm

506.1-507 cm

507.1-508 cm

508.1-509 cm

509.1-510 cm

510.1-511 cm

511.1-512 cm

512.1-513 cm

513.1-514 cm

514.1-515 cm

515.1-516 cm

516.1-517 cm

517.1-518 cm

518.1-519 cm

519.1-520 cm

520.1-521 cm

521.1-522 cm

522.1-523 cm

523.1-524 cm

524.1-525 cm

525.1-526 cm

526.1-527 cm

527.1-528 cm

528.1-529 cm

529.1-530 cm

530.1-531 cm

531.1-532 cm

532.1-533 cm

533.1-534 cm

534.1-535 cm

535.1-536 cm

536.1-537 cm

537.1-538 cm

538.1-539 cm

539.1-540 cm

540.1-541 cm

541.1-542 cm

542.1-543 cm

543.1-544 cm

544.1-545 cm

545.1-546 cm

546.1-547 cm

547.1-548 cm

548.1-549 cm

549.1-550 cm

550.1-551 cm

551.1-552 cm

552.1-553 cm

553.1-554 cm

554.1-555 cm

555.1-556 cm

556.1-557 cm

557.1-558 cm

558.1-559 cm

559.1-560 cm

560.1-561 cm

561.1-562 cm

562.1-563 cm

563.1-564 cm

564.1-565 cm

565.1-566 cm

566.1-567 cm

567.1-568 cm

568.1-569 cm

569.1-570 cm

570.1-571 cm

571.1-572 cm

572.1-573 cm

573.1-574 cm

574.1-575 cm

575.1-576 cm

576.1-577 cm

577.1-578 cm

578.1-579 cm

579.1-580 cm

580.1-581 cm

581.1-582 cm

582.1-583 cm

583.1-584 cm

584.1-585 cm

585.1-586 cm

586.1-587 cm

587.1-588 cm

588.1-589 cm

589.1-590 cm

590.1-591 cm

591.1-592 cm

592.1-593 cm

593.1-594 cm

594.1-595 cm

595.1-596 cm

596.1-597 cm

597.1-598 cm

598.1-599 cm

599.1-600 cm

600.1-601 cm

601.1-602 cm

602.1-603 cm

603.1-604 cm

604.1-605 cm

605.1-606 cm

606.1-607 cm

607.1-608 cm

608.1-609 cm

609.1-610 cm

610.1-611 cm

611.1-612 cm

612.1-613 cm

613.1-614 cm

614.1-615 cm

615.1-616 cm

616.1-617 cm

617.1-618 cm

618.1-619 cm

619.1-620 cm

620.1-621 cm

621.1-622 cm

622.1-623 cm

623.1-624 cm

624.1-625 cm

625.1-626 cm

626.1-627 cm

627.1-628 cm

628.1-629 cm

629.1-630 cm

630.1-631 cm

631.1-632 cm

632.1-633 cm

633.1-634 cm

634.1-635 cm

635.1-636 cm

636.1-637 cm

637.1-638 cm

638.1-639 cm

639.1-640 cm

640.1-641 cm

641.1-642 cm

642.1-643 cm

643.1-644 cm

644.1-645 cm

645.1-646 cm

646.1-647 cm

647.1-648 cm

648.1-649 cm

649.1-650 cm

650.1-651 cm

651.1-652 cm

652.1-653 cm

653.1-654 cm

654.1-655 cm

655.1-656 cm

656.1-657 cm

657.1-658 cm

658.1-659 cm

659.1-660 cm

660.1-661 cm

661.1-662 cm

662.1-663 cm

663.1-664 cm

664.1-665 cm

665.1-666 cm

666.1-667 cm

667.1-668 cm

668.1-669 cm

669.1-670 cm

670.1-671 cm

671.1-672 cm

672.1-673 cm

673.1-674 cm

674.1-675 cm

675.1-676 cm

676.1-677 cm

677.1-678 cm

678.1-679 cm

679.1-680 cm

680.1-681 cm

681.1-682 cm

682.1-683 cm

683.1-684 cm

684.1-685 cm

685.1-686 cm

686.1-687 cm

687.1-688 cm

688.1-689 cm

689.1-690 cm

690.1-691 cm

691.1-692 cm

692.1-693 cm

693.1-694 cm

694.1-695 cm

695.1-696 cm

696.1-697 cm

697.1-698 cm

698.1-699 cm

699.1-700 cm

700.1-701 cm

701.1-702 cm

702.1-703 cm

703.1-704 cm

704.1-705 cm

705.1-706 cm

706.1-707 cm

707.1-708 cm

708.1-709 cm

709.1-710 cm

710.1-711 cm

711.1-712 cm

712.1-713 cm

713.1-714 cm

714.1-715 cm

715.1-716 cm

716.1-717 cm

717.1-718 cm

718.1-719 cm

719.1-720 cm

720.1-721 cm

721.1-722 cm

722.1-723 cm

723.1-724 cm

724.1-725 cm

725.1-726 cm

726.1-727 cm

727.1-728 cm

728.1-729 cm

729.1-730 cm

730.1-731 cm

731.1-732 cm

732.1-733 cm

733.1-734 cm

734.1-735 cm

735.1-736 cm

736.1-737 cm

737.1-738 cm

738.1-739 cm

739.1-740 cm

740.1-741 cm

741.1-742 cm

742.1-743 cm

743.1-744 cm

744.1-745 cm

745.1-746 cm

746.1-747 cm

747.1-748 cm

748.1-749 cm

749.1-750 cm

750.1-751 cm

751.1-752 cm

752.1-753 cm

753.1-754 cm

754.1-755 cm

755.1-756 cm

756.1-757 cm

757.1-758 cm

758.1-759 cm

759.1-760 cm

760.1-761 cm

761.1-762 cm

762.1-763 cm

763.1-764 cm

764.1-765 cm

765.1-766 cm

766.1-767 cm

767.1-768 cm

768.1-769 cm

769.1-770 cm

770.1-771 cm

771.1-772 cm

772.1-773 cm

773.1-774 cm


774.1-775 cm

775.1-776 cm

776.1-777 cm

## UTSW Results – Local Control

- Median Follow-Up: 20 Months (Range: 6-53 Months)



- 12 Month & 24 Month local control

- 30Gy → 56% & 56%
- 50Gy → 100% & 89%
- 60Gy → 100% & 100%

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Stanford Experience

- Koong, et al, have published several reports using single fraction in pancreatic cancer
- Also have 18 month median follow-up on a phase II study in mostly CRC liver metastases with 30 Gy single fraction
- Recently published communication that 2 year local control is 80+% with no dose limiting toxicity

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---


---

---

---

---

## UTSW Single Fraction Trial



No. Fractions	Dose per fraction (Gy)	Total Dose (Gy)	No. Patients
1	35	35	7-15
1	40	40	7-15
1	45	45	7-15
1	50	50	7-15

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Lung Metastases

- Same story as in liver metastases
- Lung metastases are likely more radioresistant than primary lung cancer
- Lung metastases patients have healthier lungs than primary lung cancer
- University of Colorado consortium published phase I and II data

Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. *J Clin Oncol* 2009;27:1579-1584.

DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Spine Metastases

- Potential benefits
  - High and more durable local control
  - Faster pain relief
  - Potential for retreatment
  - Possibly reverse effects of cord compression
- Difficulties
  - Logistically difficult as an emergency therapy
  - Expensive compared to simple beams

DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## RTOG 0631 (Ryu, PI)

- Phase II/III trial in spinal metastases
  - Primary endpoint early complete pain relief (90 days)
- Phase II completed with good compliance
- Phase III just starting
  - Compares SABR (16-20 Gy in single fraction) to RTOG standard 8 Gy in one
  - Strict cord constraints

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## SABR as an alternative

- Some cancers already have good treatments (good control, good toxicity)
  - More difficult to show improvement
  - Can always be worse
- Breast cancer
  - SABR is convenient and may offer better cosmesis
- Prostate cancer
  - SABR is convenient and perhaps less costly

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## Partial Breast

- Non-randomized
- NSABP/RTOG trial underway

**Table 3** Cohort Studies Evaluating Hypofractionation for Partial Breast Irradiation

Study	Patients	Fractionation Schedule	Median Follow-up (mo)	Local Recurrence (%)	Cosmetic Outcome (% excellent/good)
Vicini et al., 2007 <sup>29</sup>	91	34 to 38.5 Gy/10 fractions/5 days	24	0	90
Wernick et al., 2006 <sup>30</sup>	78	30 Gy/5 fractions/10 days	28	0	92
Leonard et al., 2007 <sup>31</sup>	55	34 - 38.5 Gy/10 fractions/5 days	10	0	98
Kozak et al., 2006 <sup>32</sup>	20	32 CGE/8 fractions (proton)	12	0	100
Vicini et al., 2005 <sup>33</sup>	51	38.5 Gy/10 fractions/5 days	NR	NR	NR
Olivetto et al., 2006 <sup>34</sup>	93	35 to 38.5 Gy/10 fractions/5 to 8 days	6	NR	NR

CGE = cobalt gray equivalent; NR = not reported.

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## UTSW SABR Partial Breast Trial

- Phase I dose optimization
  - 5 fraction regimen starting at 6 Gy per fraction
- Uses a robotic linac
  - Favorable beam trajectories for anterior target
  - Fiducial tracking
- Surgically cavity with 1.5 cm expansion in most directions
- Careful evaluation of cosmetic results

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

---



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Breast: ? Problems with Hypofractionation

*Acta Oncologica*, 2009; 48: 822-831


### Hypofractionation in radiotherapy. An investigation of injured Swedish women, treated for cancer of the breast

STEN FRIBERG<sup>1</sup> & BENGT-INGE RUDEN<sup>2</sup>

For many of the women in our report, hypofractionated radiotherapy turned their lives into a disaster. They have been physically severely handicapped, some have had their careers ruined, their social relations diminished, some have had their marriages destroyed, and their economy devastated. Most of them have developed excruciating and drug-resistant pain.

- Most treated before 1980 (prior to CT planning)
- Mostly related to brachial plexopathy
  - 2 Gy equivalent dose exceeded 146 Gy per LQ model (e.g., 6 Gy X 13)
  - 6 Gy X 13 has a SFED of 20-28 Gy (for SABR, we limit SFED to 16-18)

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY




---

---

---

---

---

---

---

---

## Prostate

- Hypofractionation has equivalent results to CFRT

TABLE 1. Hypofractionation Trials: Schedules and Equivalent Doses in 2 Gy Fractions

Reference	No. Pts	Dose/Fx, Gy/Fx, Fx	Total Equivalent Dose in 2 Gy Fractions		Mod. RT, Gy	Interval, wk	Risk, %	WGrade 1 Late Toxicity, %	
			$\alpha/\beta = 1.5$ (Gy)	$\alpha/\beta = 3$ (Gy)				CF	CFRT
Lewy et al <sup>1</sup> Manchester	305	56 Gy/11 Gy/16 Fx	66 Gy	63.5 Gy	48	34 (1 yr)	3	9	—
Alpert et al <sup>2</sup> Gosses	52	66 Gy/13.2 Gy/16 Fx	66.7 Gy	62.8 Gy	33	—	25	—	—
Tsang et al <sup>3</sup> Chiba	201	66 Gy/13.2 Gy/20 Fx	66.5 Gy	63.1 Gy	30	97	2	6	—
Fligstein et al <sup>4</sup> Edinburgh	300	52.5 Gy/10.5 Gy/20 Fx	63.8 Gy	59.1 Gy	12	55	—	—	—
Swan et al <sup>5</sup> Limerick	56	76 Gy/15.2 Gy/16 Fx	80 Gy	73.8 Gy	—	—	—	—	—
Marquet et al <sup>6</sup> Princess Margaret	92	66 Gy/13.2 Gy/20 Fx	77.2 Gy	72 Gy	36	85	4	3	—
Kaplan et al <sup>7</sup> M.D. Anderson	770	76 Gy/15.2 Gy/20 Fx	80 Gy	77 Gy	45	85	4.5	5.5	—
Ritter et al <sup>8</sup> Wisconsin	100	64.7 Gy/12.94 Gy/22 Fx	62.6 Gy	77 Gy	39	95	8.5	1	—
Larkin et al <sup>9</sup> NCIC	80 (control)	51.8 Gy/10.36 Gy/16 Fx	63.3 Gy	73 Gy	34	—	—	—	—
	400	55.5 Gy/11.1 Gy/16 Fx	63.5 Gy	70.1 Gy	48	40	1.3	1.9	—
	470	66 Gy/13.2 Gy/20 Fx	66 Gy	66 Gy	—	—	—	—	—
York et al <sup>10</sup> Adjuvant	198	55 Gy/11 Gy/20 Fx	63.5 Gy	63.2 Gy	48	57.4	Abnormal morning	—	—
Pollack et al <sup>11</sup> Prostate Cancer	100	64 Gy/12.8 Gy/16 Fx	64 Gy	64 Gy	—	55.5	—	—	—
	100	70.2 Gy/14.04 Gy/16 Fx	64.2 Gy	64 Gy	—	—	—	—	—
	100	76 Gy/15.2 Gy/16 Fx	76 Gy	76 Gy	—	—	—	—	—
Khan et al <sup>12</sup> M.D. Anderson	Open, 100	76 Gy/15.2 Gy/16 Fx	64 Gy	77 Gy	—	—	—	—	—
	Open, 100	76 Gy/15.2 Gy/16 Fx	64 Gy	77 Gy	—	—	—	—	—
Khan et al <sup>13</sup> M.D. Anderson	Open, 100	76 Gy/15.2 Gy/16 Fx	64 Gy	77 Gy	—	—	—	—	—
	Open, 100	76 Gy/15.2 Gy/16 Fx	64 Gy	77 Gy	—	—	—	—	—

From Ritter et al Semin Radiat Oncol 18:249-256 © 2008

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## What is the $\alpha/\beta$ for prostate cancer?

- Some have made a career addressing this question
- Alpha and beta describe the radiation survival curve specifically within the shoulder region
- Hypofractionation is a treatment delivered near or beyond the shoulder region
  - Alpha and beta affect treatments near BUT not beyond the shoulder
- If SABR is delivered past the shoulder, then  $\alpha/\beta$  is IRRELEVANT
  - All that matters beyond the shoulder is  $D_0$


**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

## Treatment Near or Beyond “Shoulder”

- Multi-target model
  - $D_q$  (x-intercept – shoulder width)
  - $D_0$  (slope – sensitivity beyond shoulder)
- Even more precisely, per Park, et al., (Universal Survival Model)
  - The “Transition Dose” between LQ (realm of repair) and pure target theory

$$D_T = \frac{2 \cdot D_q}{1 - \alpha \cdot D_0}$$

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY



## “Hypofractionation” Varies

Shoulder Broadness

Tissue Type	D <sub>q</sub> (Gy)	D <sub>T</sub> (Gy)	D <sub>0</sub> (Gy)
H460 (NSCLC)	1.8	6.13	1.25
DU-145 (Prostate CA)	1.91	3.55	1.91
PC-3 (Prostate CA)	1.02	4.22	1.06
Squamous CA (oxic)	4.89	16.01	1.06
Squamous CA (hypoxic)	22.82	84.98	1.58
Brain	10.23	22.39	1.2
Bone	8.4	18.96	1.67
Gut	7.61	21.54	1.64
Skin	2.7	6.84	1.11
Connective Tissue	4.24	9.74	1.49
Kidney	0.46	1.8	1.46

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

Ease of kill  
beyond shoulder

## SABR in Prostate Cancer

- Mix of low and intermediate risk
- Madsen dose seems too low
- Perhaps highest UTSW dose is too high
- ? What is just right

References	No. Pts	Dose/Fx Size/No. Fxs	Total Equivalent Dose in 2 Gy Fractions (EQD <sub>2</sub> )		Mod. FU (mo)	≥Grade 2 Late Toxicity (%)	
			$\alpha/\beta = 1.5$ (Tumor)	$\alpha/\beta = 3$ (Late Effects)		GI	GU
Madsen et al <sup>10</sup> Virginia Mason	40	33.5 Gy/6.7 Gy/5 fx	78 Gy	64.9 Gy	41	7.5	20
King et al <sup>10</sup> Stanford	41	36.25 Gy/7.25 Gy/5 fx	90.6 Gy	74.3 Gy	33	15	29
Widmark (personal communication, 2008) Umea	105	42.7 Gy/8.5 Gy/7 fx	92.7 Gy	77.7 Gy	—	—	—
Tang et al <sup>11</sup> Univ. Toronto	30	35 Gy/7 Gy/5 fx	85.1 Gy	70 Gy	12	13	13
Timmerman (personal communication, 2008)	15	47.5 Gy/9.5 Gy/5 fx	149 Gy*	118 Gy	—	—	—
UTSW, Dallas	10 (ongoing)	50 Gy/10 Gy/5 fx	164 Gy	130 Gy	—	—	—
	—	52.5 Gy/10.5 Gy/5 fx	180 Gy	142 Gy	—	—	—

\*The EQD<sub>2</sub> doses based on linear quadratic modeling may overpredict the biologically equivalent dose for large fractions, as in the University of Texas Southwestern trial.

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

From Ritter et al *Semin Radiat Oncol* 18:249-256 © 2008

Freeman and King *Radiation Oncology* 2011, 63  
<http://www.ox-journals.com/content/63/1/3>



## Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Debra E. Freeman<sup>1\*</sup>, Christopher R. King<sup>2</sup>

- 2 centers pooled data
- Low risk patients
- 35-36.25 Gy in 5 fractions using Cyberknife




Figure 1 Kaplan-Meier biochemical disease-free survival curve after SBRT for prostate cancer. Median follow-up is 5 years. Three of the 41 patients received at 35, 37 and 40 months post-treatment. Tick marks indicate censored patients.

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

Table 1 Late urinary and rectal toxicity on the RTOG scale for prostate cancer patients after SBRT

RTOG Grade	I	II	III	IV
Urinary	25% (10/41)	7% (3/41)	2.5% (1/41)	0%
Rectal	13% (6/41)	2.5% (1/41)	0%	0%



Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.31.4377  
The latest version is at <http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2010.31.4377>

**JOURNAL OF CLINICAL ONCOLOGY** ORIGINAL REPORT

**Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer**

Thomas P. Baile, Yair Lotan, L. Chinsoo Cho, Jeffrey Brindle, Paul DeRose, Xian-Jin Xie, Jingsheng Yan, Ryan Foster, David Pistenmaa, Ahda Perkins, Susan Cooley, and Robert Tinnerman

- Dose escalation in the higher ranges
  - Low and intermediate risk
  - Used daily enema and daily rectal balloon
  - Safely escalated to 45, 47.5, and 50 Gy in 5 fractions using linac
- Currently enrolling to Phase II trial
  - Margins are down to 2 mm per image guidance

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### Hypofractionation: Then and Now

**SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

### Conventional Radiation vs. SBRT Dosimetry

Targets (blue - GTV, red - PTV)

6000 cGy (script dose)

Postage Stamp      SBRT

**A paradigm changing difference!**

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

### Tumor Burden In Oncology

- Piles of bricks
  - Microscopic disease (1-8 logs)
  - Small volume gross disease (8-9 logs)
  - Bulky gross disease (>9 logs)

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

### Definitive Surgery

T		
N		
M		

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---







---


---

---

---

### Definitive Radiotherapy

T			
N			
M			

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

### Definitive Systemic Therapy

T			
N			
M			

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---

---






---


---

---

---

### Future Definitive Surgery

T			
N			
M			

 SOUTHWESTERN  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Future Definitive Radiotherapy

T



N



M



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Future Definitive Systemic Therapy

T



N



M



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---

## Conclusions

- SABR for primary lung cancer is effective and tolerable
  - Prospectively studied by hypothesis driven clinical trials
  - Encouraging and reproducible results
- Building on the primary lung experience, primary and metastatic tumors of the liver and metastatic tumors of the lung constitute a new indication for radiotherapy
- Spine metastases are being evaluated in a phase III trial
- Bread and butter indications (prostate and breast) need to show lack of downsides (since upsides are less likely) prior to general acceptance

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

---

---

---

---

---

---

---

---


## Acknowledgements

- UTSW Rad Onc
  - Hak Choy, M.D.
  - Ramzi Abdulrahman, M.D.
  - Lucien Nedzi, M.D.
  - Lech Papiez, Ph.D.
  - Timothy Solberg, Ph.D.
- UTSW CT Surgery
  - Michael Wait, M.D.
  - Michael Dimiao, M.D.
- UTSW Med Onc
  - Joan Schiller, M.D.
  - David Gerber, M.D.
- RTOG Headquarters
  - Rebecca Paulus, Ph.D.
  - Linda Walters, M.S.
- RTOG Collaborators
  - Jeff Bradley, M.D.
  - Harvey Pass, M.D.
- RPC
  - Geoff Ibbott, Ph.D.
  - David Followill, Ph.D.
- ATC/ITC
  - Jeff Michalski, M.D.
  - Walter Bosch, Ph.D.
  - Bill Straube, Ph.D.

**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY

Which of the following statements regarding dose response relationships for ablative radiotherapy delivery is FALSE

1. Dose response relationships are best determined by phase I clinical trials
2. Small dose increase may result in large toxicity increase in the transition range of the dose response curve.
3. The Maximum Tolerated Dose (MTD) corresponds to the most ideal therapeutic ratio.
4. A negative therapeutic window results when efficacy is less likely than harm.




### The Maximum Tolerated Dose (MTD) corresponds to the most ideal therapeutic ratio

- The only variable in a phase I trial is dose making it an ideal platform for studying dose response effects. The slope of the dose response curve is greatest in the transition region. In contrast to most chemotherapy regimens, the widest therapeutic window for SABR in lung cancer occurred at a dose considerably lower than the MTD (slide 10). If response curves for efficacy and toxicity cross (e.g., at higher dose levels), the therapeutic window will be negative.
- Ref: Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2007;2:S101-12

Early stage lung cancer was the most common clinical model studied in clinical trials testing SABR at centers across the world. The Indiana University trials demonstrated that treatments in the central chest were problematic for patients to tolerate likely related to:

1. Impairment of the pulmonary toilet function of the central chest.
2. Higher dose used for central tumors
3. Larger tumors generally occurring in the central chest
4. Differential tolerance of parallel vs. secular defined thoracic structures



#### Impairment of the pulmonary toilet function of the central chest

- Proximal airways facilitate the clearing of secretions within the lung by their expectorant and ciliary functions (slide 26). The Indiana University phase II trial used a narrow range of highly potent 3 fraction dose levels. Toxicity was observed both for T1 and T2 tumors. Ablative dose treatment shows distinct response between parallel and serial (not secular) structures.
- Ref: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer

Based on published reports, what factors would be most concerning for increased risk of toxicity after SABR?

- |     |                             |
|-----|-----------------------------|
| 13% | 1. impaired spirometry      |
| 2%  | 2. peripheral lung location |
| 80% | 3. impaired DLCO            |
| 6%  | 4. advanced age             |

**impaired DLCO**

- Published reports indicate that DLCO is compromised more than spirometry after SBRT<sup>2</sup> (slide 21). The opposite is true for surgical resections.
- Ref: Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-55.

---

---

---

---


---

---

---

The following are true statements about the outcome of patients with early stage lung cancer treated with SBRT?

- Local control for this treatment is predicted to be >80%.
- Risk of grade 3 or higher toxicity is around 20% at 3 years.
- Overall survival in most series is 60-75% at 2 years.
- All of the above



---

---

---

---

---

---

---

**All of the above**

---

---

---

---


---

---

---

The rationale and conduct for SABR treatment in metastatic cancer to the liver includes all of the following except:


1. Treatment intent is to improve survival, even cure.
2. Previous chemotherapy clearly limits tolerance and is a contraindication to using SABR in patients with liver metastases.
3. The University of Colorado multicenter trials used the critical volume methodology to avoid liver toxicity
4. Dose tolerance of the liver is similar to treatments in the lung



**Previous chemotherapy clearly limits tolerance and is a contraindication to using SABR in patients with liver metastases.**

- Patients with oligometastases from metastatic cancers (e.g., colorectal cancer) can be cured with metastectomy. Most patients treated in clinical trials testing SABR had already progressed after 1<sup>st</sup> and 2<sup>nd</sup> line (even 3<sup>rd</sup> line) chemotherapy (slide 47). The critical volume is the volume of organ necessary to avoid a defined clinical insufficiency. The critical volume must be spared (ie, not exceed) a threshold dose. The University of Colorado studies used this model allowing dose escalation to potent tumoricidal dose, similar to the Indiana University phase I/II studies in lung cancer.

Happy Trials!



**UT SOUTHWESTERN**  
DEPT OF RADIATION ONCOLOGY